Timotheus Jansen

Timotheus (Tim) Jansen, MD, PhD, joined Olatec’s Drug Development Team in February 2016 and became a Chairman of the Clinical Advisory Board in February 2019. Dr. Jansen has been contributing leading expertise in the design and conduct of Olatec’s human clinical trials in gout, including serving as Principal Investigator in the first and second clinical trial with dapansutrile for acute gout flares. He has over 20 years of clinical experience in both academic positions and private practice in rheumatology focused on gouty arthritis. Dr. Jansen is currently the Head of the Department of Rheumatology at VieCuri Medisch Centrum/Northern Limburg, Venlo, the Netherlands. From 2006-2012, Dr. Jansen was a Board member of the Dutch Society of Rheumatology and presided on its Quality Committee and he coauthored “Consumer Quality index in RA”, the national guideline: “Diagnosis and treatment of RA”, the national set of “quality indicators of RA”, and the national guideline: “Appropriate use of Biologicals in rheumatic diseases”. In addition, he has published over 200 PubMed publications covering cardiovascular and rheumatology topics. He is a member of the editorial board of Clinical Rheumatology and reviewer for several Rheumatology journals. Dr. Jansen was trained in Internal Medicine and Rheumatology at Academic Hospital St. Radboud, Nijmegen, the Netherlands and Rijnstate Hospital, Arnhem, the Netherlands, where he received his PhD in April 1993.